|
Schirdewan博士的引述的參考文獻:
5 v! Z, P% |; `; M! w0 I
# T- d! T: _% |: jCamm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009.
+ f: e6 Y6 o' T) {, ?! X5 `! r( m! m: h( S3 z7 v
Daubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
, T" C2 ^# P; h1 P2 N4 n
5 w+ |0 J9 V4 P A; W5 s& c5 S6 eRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. * G( Q- A& L6 @9 A# o4 @9 U
6 U$ {! ^/ } I- {$ u關於BIOTRONIK SE & Co. KG! v8 ?7 A: P' Q
, O/ A- Y% {8 c, o
BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|